Puerto Rico's drug production sector has had an eventful few years, with investments by Eli Lilly, Bristol-Myers Squibb and others being offset by cutbacks at Merck and Pfizer. Now the island can add another line to its list of positive events: Actavis is investing $48 million to revitalize assets it acquired in the takeover of Warner Chilcott.
New sales models are trendy in Big Pharma. Actually, they're de rigueur: With thousands fewer drug reps on the street these days, and many doctors turning reps away, companies have had to turn to new ways of promoting their products. Plus, all those pesky Department of Justice settlements make the old hard sell seem sketchy.
If Sanofi and Eli Lilly have their way, men wouldn't need to ask their doctors to prescribe an erectile dysfunction remedy. They'd simply drive to the drugstore. And that could keep Cialis, one of Lilly's most successful products, on the list of top moneymakers after its patent expires.
With thousands fewer drug reps on the street these days, and many doctors turning reps away, companies have had to turn to new ways of promoting their products. What's Eli Lilly's version? According to an interview with Alex Azar, president of the Indianapolis-based company's U.S. business, it's problem-solving.
Over the past decade patent expiries have forced many Big Pharma to close production plants that supported decades of growth. With the current and next generations of small molecules and biologics raising the bar for manufacturing complexity, Eli Lilly, Merck and their peers face a choice: build plants or outsource?
After a manufacturing issue spiked its pitch for FDA approval, a new diabetes drug from Eli Lilly and Boehringer Ingelheim has secured European clearance, lining up to compete in a crowded market.
Just weeks after a federal jury in Louisiana gut-punched Takeda and Eli Lilly with a $9 billion verdict over diabetes drug Actos, an Illinois jury promptly let the company off the hook.
Eli Lilly lost a patent fight with Actavis in English High Court, in a ruling that paves the way for copycat competition not only in that country, but several others in Europe.
Eli Lilly has hotly denied and intends to fight the findings of a court in Brazil that could cost it nearly half a billion dollars to cover medical costs for former employees.
Eli Lilly in 2003 sold an antibiotics manufacturing plant in Cosmopolis, Brazil, to Italy's ACS Dobfar. But the fact that it has been more than a decade since Eli Lilly owned the facility has not kept the company from being ordered to pay $450 million to cover medical costs of dozens of plant employees for health problems they said came from exposure to hazardous materials.